Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

被引：0
|
作者：
Pardanani, Animesh
Harrison, Claire N.
Cortes, Jorge E.
Cervantes, Francisco
Mesa, Ruben A.
Milligan, Donald
Masszi, Tamas
Mishchenko, Elena
Jourdan, Eric
Vannucchi, Alessandro M.
Drummond, Mark
Jurgutis, Mindaugas
Kuliczkowski, Kazimierz
Gheorghita, Emanuil
Passamonti, Francesco
Neumann, Frank
Gao, Guozhi
Tefferi, Ayalew
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
393
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    A Pardanani
    A Tefferi
    C Jamieson
    N Y Gabrail
    C Lebedinsky
    G Gao
    F Liu
    C Xu
    H Cao
    M Talpaz
    Blood Cancer Journal, 2015, 5 : e335 - e335
  • [2] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    Pardanani, A.
    Tefferi, A.
    Jamieson, C.
    Gabrail, N. Y.
    Lebedinsky, C.
    Gao, G.
    Liu, F.
    Xu, C.
    Cao, H.
    Talpaz, M.
    BLOOD CANCER JOURNAL, 2015, 5 : e335 - e335
  • [3] Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelofibrosis (MF)
    Pardanani, Animesh Dev
    Jamieson, Catriona H. M.
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Gao, Guozhi
    Patki, Abhay
    Liu, Feng
    Tefferi, Ayalew
    Talpaz, Moshe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis
    Jamieson, Catriona H. M.
    Hasserjian, Robert P.
    Gotlib, Jason
    Cortes, Jorge E.
    Stone, Richard M.
    Talpaz, Moshe
    Thiele, Juergen
    Rodig, Scott
    Patki, Abhay
    Wu, Kaida
    Wu, Jingyang
    Pozdnyakova, Olga
    BLOOD, 2013, 122 (21)
  • [5] MODULATION OF PLASMA CYTOKINES AND ITS ASSOCIATION WITH CLINICAL RESPONSE TO TREATMENT WITH THE JAK2-SELECTIVE INHIBITOR SAR302503 IN A PHASE 2 STUDY OF PATIENTS WITH MYELOFIBROSIS (MF)
    Talpaz, M.
    Jamieson, C.
    Gabrail, N.
    Lebedinsky, C.
    Liu, F.
    Cao, H.
    Tefferi, A.
    Pardanani, A.
    HAEMATOLOGICA, 2013, 98 : 117 - 117
  • [6] A Randomized, Placebo-Controlled Study of the Pharmacokinetics, Pharmacodynamics, and Tolerability of the Oral JAK2 Inhibitor Fedratinib (SAR302503)in Healthy Volunteers
    Zhang, Meng
    Xu, Christine R.
    Shamiyeh, Elias
    Liu, Feng
    Yin, Jian Y.
    von Moltke, Lisa L.
    Smith, William B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (04): : 415 - 421
  • [7] Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in myelofibrosis (MF)
    Talpaz, Moshe
    Jamieson, Catriona H. M.
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Liu, Feng
    Cao, Hui
    Tefferi, Ayalew
    Pardanani, Animesh Dev
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)
    Talpaz, M.
    Jamieson, C.
    Gabrail, N.
    Lebedinsky, C.
    Gao, G.
    Patki, A.
    Lui, F.
    Tefferi, A.
    Pardanani, A.
    HAEMATOLOGICA, 2013, 98 : 458 - 458
  • [9] Effect of Food on the Bioavailability and Tolerability of the JAK2-Selective Inhibitor Fedratinib (SAR302503): Results From Two Phase I Studies in Healthy Volunteers
    Zhang, Meng
    Xu, Christine
    Ma, Lei
    Shamiyeh, Elias
    Yin, Jianyun
    von Moltke, Lisa L.
    Smith, William B.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (04): : 315 - 321
  • [10] JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly
    Pardanani, Animesh Dev
    Cortes, Jorge E.
    Cervantes, Francisco
    Harrison, Claire N.
    Passamonti, Francesco
    Lebedinsky, Claudia
    Neumann, Frank
    Cohen, Pamela
    Tefferi, Ayalew
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345